NAS:DVAX (USA) Also trade in: Germany UK

Dynavax Technologies Corp

$ 6.36 -0.19 (-2.9%)
Volume: 611,206 Avg Vol (1m): 1,194,395
Market Cap $: 413.83 Mil Enterprise Value $: 406.29 Mil
P/E (TTM): 0.00 P/B: 9.40
Earnings Power Value -180.03
Net Current Asset Value -0.48
Tangible Book 0.5
Projected FCF -14.64
Median P/S Value 6.53
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.04
Cash-To-Debt ranked lower than
71.06% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
DVAX: 1.04
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.04, Med: 10000, Max: 10000
Current: 1.04
1.04
10000
Equity-to-Asset 0.15
Equity-to-Asset ranked lower than
71.56% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
DVAX: 0.15
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -2.28, Med: 0.75, Max: 0.94
Current: 0.15
-2.28
0.94
Debt-to-Equity 4.07
Debt-to-Equity ranked lower than
78.20% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
DVAX: 4.07
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -7.14, Med: 0.31, Max: 4.07
Current: 4.07
-7.14
4.07
Debt-to-EBITDA -1.33
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
DVAX: -1.33
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.33, Med: -0.28, Max: -0.11
Current: -1.33
-1.33
-0.11
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.13
DISTRESS
GREY
SAFE
Beneish M-Score 38.99
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -760.44%
WACC 7.91%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -1107.19
Operating Margin ranked lower than
91.16% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
DVAX: -1107.19
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -28508.26, Med: -760.03, Max: -37.49
Current: -1107.19
-28508.26
-37.49
Net Margin % -1156.11
Net Margin ranked lower than
91.41% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
DVAX: -1156.11
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -29099.08, Med: -771.22, Max: -75.81
Current: -1156.11
-29099.08
-75.81
ROE % -159.47
ROE ranked lower than
66.13% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
DVAX: -159.47
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -307.22, Med: -70.1, Max: -49.94
Current: -159.47
-307.22
-49.94
ROA % -61.25
ROA ranked lower than
67.16% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
DVAX: -61.25
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -85.08, Med: -55.43, Max: -38.75
Current: -61.25
-85.08
-38.75
ROC (Joel Greenblatt) % -802.87
ROC (Joel Greenblatt) ranked lower than
55.31% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
DVAX: -802.87
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1090.64, Med: -779.73, Max: -172.67
Current: -802.87
-1090.64
-172.67
3-Year Total Revenue Growth Rate 26.50
3-Year Revenue Growth Rate ranked lower than
88.33% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
DVAX: 2.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -27.4, Max: 88.2
Current: 2.1
0
88.2
3-Year Total EBITDA Growth Rate -8.80
3-Year EBITDA Growth Rate ranked higher than
70.82% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
DVAX: 12.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -39.1, Med: 12.25, Max: 63.3
Current: 12.1
-39.1
63.3
3-Year EPS w/o NRI Growth Rate 7.80
3-Year EPS w/o NRI Growth Rate ranked higher than
67.63% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
DVAX: 7.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -26.3, Med: 18.2, Max: 60.6
Current: 7.8
-26.3
60.6

» DVAX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:DVAX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XKRX:196170 ASX:PNV SHSE:600556 NAS:TBIO NAS:CTMX SZSE:300705 SHSE:603538 XKRX:052020 NAS:SRNE NAS:PDLI NYSE:RCUS NAS:AVRO NAS:ANIK NAS:PRQR NAS:ELOX NAS:PRTA NAS:FPRX NAS:KRYS NAS:ADVM NAS:ACHN
Traded in other countries DYF1.Germany 0IDA.UK
Address 2929 Seventh Street, Suite 100, Berkeley, CA, USA, 94710-2753
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax operates in the business segment the discovery and development of biopharmaceutical products. Its Toll-like Receptor Immune Modulation Platform technology play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to the generation of innate immunity.

Ratios

Current vs industry vs history
PB Ratio 9.40
PB Ratio ranked lower than
66.42% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
DVAX: 9.4
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.65, Med: 4.93, Max: 14.94
Current: 9.4
0.65
14.94
PS Ratio 29.03
PS Ratio ranked lower than
93.80% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
DVAX: 29.03
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.18, Med: 29.82, Max: 3308.33
Current: 29.03
0.18
3308.33
EV-to-EBIT -2.75
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
DVAX: -2.75
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -26.2, Med: -4, Max: 6.3
Current: -2.75
-26.2
6.3
EV-to-EBITDA -3.07
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
DVAX: -3.07
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -16.3, Med: -4, Max: 32.5
Current: -3.07
-16.3
32.5
EV-to-Revenue 29.44
EV-to-Revenue ranked lower than
90.79% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
DVAX: 29.44
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -1.6, Med: 23.1, Max: 3122.3
Current: 29.44
-1.6
3122.3
Current Ratio 5.27
Current Ratio ranked higher than
73.09% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
DVAX: 5.27
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.87, Med: 6.2, Max: 15.29
Current: 5.27
1.87
15.29
Quick Ratio 4.61
Quick Ratio ranked higher than
73.18% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
DVAX: 4.61
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.87, Med: 6.07, Max: 15.29
Current: 4.61
1.87
15.29
Days Inventory 203.19
Days Inventory ranked higher than
79.42% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
DVAX: 203.19
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 47.69, Med: 104.79, Max: 203.19
Current: 203.19
47.69
203.19
Days Sales Outstanding 153.10
Days Sales Outstanding ranked lower than
96.56% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
DVAX: 153.1
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 8.1, Med: 45.27, Max: 953.24
Current: 153.1
8.1
953.24
Days Payable 186.34
Days Payable ranked higher than
66.98% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
DVAX: 186.34
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 88.39, Med: 737.97, Max: 1387.55
Current: 186.34
88.39
1387.55

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -17.50
3-Year Share Buyback Rate ranked lower than
76.31% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
DVAX: -17.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -180.4, Med: -29.8, Max: -9.4
Current: -17.5
-180.4
-9.4

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 12.72
Price-to-Tangible-Book ranked lower than
63.87% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
DVAX: 12.72
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.73, Med: 4.54, Max: 27.68
Current: 12.72
1.73
27.68
Price-to-Median-PS-Value 0.97
Price-to-Median-PS-Value ranked lower than
98.82% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
DVAX: 0.97
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.02, Med: 0.77, Max: 110.28
Current: 0.97
0.02
110.28
Earnings Yield (Joel Greenblatt) % -36.53
Earnings Yield (Greenblatt) ranked lower than
67.81% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
DVAX: -36.53
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1045.3, Med: -22.85, Max: 1872.4
Current: -36.53
-1045.3
1872.4

More Statistics

Revenue (TTM) (Mil) $ 13.81
EPS (TTM) $ -2.54
Beta 0.7
Volatility % 45.98
52-Week Range $ 5.89 - 17.25
Shares Outstanding (Mil) 65.07

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y